Incomplete Conditional PMA Studies Are Target Of FDA Scrutiny
This article was originally published in The Gray Sheet
FDA has begun contacting sponsors of approved premarket approval applications with incomplete conditional postmarket studies to assess the status of the investigations.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.